ArticleCancer immunology, immunotherapy : CII2025
The immunophenotype of immune checkpoint-induced bullous pemphigoid: a cohort study.
Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- An atypical presentation of Pembrolizumab-induced bullous pemphigoid in a patient with uterine serous carcinoma.Gynecologic oncology reports · 2026Article
- Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients.Acta dermato-venereologica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) are increasingly used in cancer therapy and have been linked to adverse dermatologic effects, including bullous pemphigoid (BP), which may necessitate treatment interruption. This study aims to characterize the immunologic profile of ICI-induced BP (BPICI) and identify associated autoantibodies. We conducted a retrospective cohort study (2015-2022) at Rambam Health Care Campus, including patients aged ≥ 18 years who received anti-PD-1/PD-L1 therapy and developed BP. Controls included (1) patients with non-BP cutaneous adverse events (NBPICI), (2) ICI-treated patients without cutaneous immune-related adverse events (irAEs) (NirAEICI), and (3) BP patients not treated with ICIs (BPNICI). Sera were analyzed via ELISA for BP180NC16A, BP230, Dsg1, Dsg3, and collagen VII autoantibodies. Of 242 patients with cutaneous irAEs, 16 patients were diagnosed with BP (BPICI group), and 11 patients had sera available for analysis. ELISA detected BP180NC16A antibodies in 81.8% of BPICI cases, while other autoantibodies were negative in all but one case. BPICI patients were significantly older (p < 0.05), more often male (p = 0.0066), and predominantly had cutaneous squamous cell carcinoma (SCC, 43.8%). Patients with SCC had a significantly increased hazard ratio (HR 9.41, 95% confidence interval (CI) 3.43-25.77) for BP development. BP onset occurred later in BPICI (mean 61.3 weeks) than in other irAEs (mean 32.2 weeks), but latency did not differ according to cancer type. BPICI patients required higher average daily prednisone doses per kilogram body weight during the first six months compared to BPNICI (p < 0.05). Most patients (66.6%) permanently discontinued ICI therapy due to BP. Our findings suggest that ICI-induced BP shares a similar immunologic profile with classic BP, without evidence of antigen spreading, and that SCC patients are at greater risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.